SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer
12 references·2 citing·42 second hop
Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer (2011)Updated Cost-Effectiveness Analysis of Tr…A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice (2012)A Systematic and Critical Rev…Health related quality of life in different states of breast cancer (2007)Health related quality of lif…Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer (2007)Cost‐effectiveness analysis o…Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer (2007)Cost-effectiveness of HER2 te…Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer (2007)Cost Effectiveness of Trastuz…Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (2007)Cost Effectiveness of Adjuvan…A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer (2007)A Cost-Effectiveness Analysis…Decision Modelling For Health Economic Evaluation (2006)Decision Modelling For Health…The Impact of Chronic Heart Failure on Health-Related Quality of Life Data Acquired in the Baseline Phase of the CARE-HF Study (2005)The Impact of Chronic Heart F…HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis (2004)HER-2 Testing and Trastuzumab…Handling Uncertainty in Cost-Effectiveness Models (2000)Handling Uncertainty in Cost-…Markov Models in Medical Decision Making (1993)Markov Models in Medical Deci…Cost-effectiveness analysis of 3D image-guided brachytherapy compared with 2D brachytherapy in the treatment of locally advanced cervical cancer (2014)Cost-effectiveness analysis o…Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force (2013)Consolidated Health Economic …EuroQol - a new facility for the measurement of health-related quality of life (1990)Cost-Effectiveness in Health and Medicine (1996)Methods for the Economic Evaluation of Health Care Programmes (2005)Health-state utility values in breast cancer (2010)What Patients Can Tell Us: Topic Analysis for Social Media on Breast Cancer (2017)Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare (2018)Panel on cost-effectiveness in health and medicine. (1996)Recommendations for Reporting Cost-effectiveness Analyses (1996)Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine (1996)Cost effectiveness of gene expression profiling for early stage breast cancer (2012)The economic pressures for biosimilar drug use in cancer medicine (2012)Measurement of health state utilities for economic appraisal (1986)Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease (2002)Review of guidelines for good practice in decision-analytic modelling in health technology assessment (2004)Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment (2006)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer (2015)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. (2009)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement (2016)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)EuroQol: the current state of play (1996)Modeling Valuations for EuroQol Health States (1997)Variations in population health status: results from a United Kingdom national questionnaire survey (1998)Poor sleep and impaired self-care: Towards a comprehensive model linking sleep, cognition, and heart failure outcomes (2009)Health-Related Quality of Life as Measured with EQ-5D among Populations with and without Specific Chronic Conditions: A Population-Based Survey in Shaanxi Province, China (2013)Validity of the 12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD) (2015)Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer (1991)The Beaver Dam Health Outcomes study (1993)Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? (2008)XXIV. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. In a letter to Francis Baily, Esq. F. R. S. &c (1825)Foundations of Cost-Effectiveness Analysis for Health and Medical Practices (1977)The Markov Process in Medical Prognosis (1983)An Introduction to Markov Modelling for Economic Evaluation (1998)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Evidence Synthesis for Decision Making 2 (2012)Model Parameter Estimation and Uncertainty Analysis (2012)
this work references cited by second hop

References

  • 2006Decision Modelling For Health Economic Evaluation3,146 cited
  • 1993Markov Models in Medical Decision Making2,446 cited
  • 2000Handling Uncertainty in Cost-Effectiveness Models806 cited
  • 2004HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis230 cited
  • 2007Health related quality of life in different states of breast cancer224 cited
  • 2005The Impact of Chronic Heart Failure on Health-Related Quality of Life Data Acquired in the Baseline Phase of the CARE-HF Study216 cited
  • 2007Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer140 cited
  • 2007Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer120 cited
  • 2007A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer119 cited
  • 2012A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice81 cited
  • 2007Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer81 cited
  • 2007Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer64 cited

Cited by

  • 2013Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2,025 cited
  • 2014Cost-effectiveness analysis of 3D image-guided brachytherapy compared with 2D brachytherapy in the treatment of locally advanced cervical cancer48 cited